WHO Prequalification of Diagnostics Programme
PUBLIC REPORT

Product: Genscreen™ ULTRA HIV Ag-Ab
Number: PQDx 0096-031-00

Abstract

Genscreen™ ULTRA HIV Ag-Ab with product codes 72386 and 72388, manufactured by Bio-Rad, CE-marked regulatory version, was accepted for the WHO list of prequalified diagnostics and was listed on 08 April 2013.

Genscreen™ ULTRA HIV Ag-Ab is a qualitative enzyme immunoassay for the detection of HIV-1 p24 antigen and antibodies to HIV-1 (groups M and O) and HIV-2 in human serum or plasma.

Genscreen™ ULTRA HIV Ag-Ab is an enzyme immunoassay based on the principle of the sandwich technique for the detection of HIV antigen and of the various antibodies associated with HIV-1 and/or HIV-2 virus in human serum or plasma.

The solid phase is coated with:
- monoclonal antibodies against p24 HIV-1 antigen and
- purified antigens: gp160 recombinant protein, a synthetic peptide mimicking a totally artificial (i.e. encoded by no existing virus) HIV-1 group O-specific epitope and a peptide mimicking the immunodominant epitope of the HIV-2 envelope protein.

The conjugates are based upon the use of:
- biotinylated polyclonal antibodies to HIV Ag (conjugate 1) and
- streptavidin-peroxydase conjugate and HIV antigens - peroxidase conjugate (gp41 and gp36 peptides mimicking the immunodominant epitopes of the HIV-1 and HIV-2 envelope glycoproteins, and the same synthetic peptide mimicking a totally artificial HIV-1 group O-specific epitope used for the solid phase) (conjugate 2).

The assay procedure includes the following reaction steps:
1. Conjugate 1 (biotinylated polyclonal antibody to p24 HIV-1 Ag) is added into the microplate wells.
2. Serum/plasma samples to be assayed and controls are pipetted and added into the wells.
   • If present, HIV antigens bind with the monoclonal antibody bound to the solid phase and the conjugate 1
• HIV-1 and/or HIV-2 antibodies, if any, bind to the antigens immobilised on the solid phase.
• Deposition of conjugate 1 and sample is validated through a colour change, from yellow-green to blue.
3. After incubation at 37°C then washing, conjugate 2 is added:
• Streptavidin-peroxydase will react with biotinylated Ab-Ag-Ab complexes
• Peroxidase-labelled purified HIV-1 and HIV-2 antigens bind in turn to the IgG, IgM or IgA antibodies captured on the solid phase.
4. After incubation at 18-30°C, the unbound conjugate 2 fraction is removed by washing.
After incubation in presence of the substrate at room temperature (18-30°C) the presence of the complexed conjugate is shown by a change of colour.
5. The reaction is stopped and absorbances are read using a spectrophotometer at 450/620-700 nm.
The absorbance measured on a sample determines the presence or absence of HIV Ag or HIV-1 and/or HIV-2 antibodies.

Every reactive result (in accordance with the interpretation criteria of Genscreen™ ULTRA HIV Ag-Ab test) should be confirmed with an appropriate method.

The test kit is marketed the following different configurations:

1. Genscreen™ ULTRA HIV Ag-Ab with product code 72386:
   • **R1 Microplate** 12 strips of 8 wells coated with monoclonal antibodies to p24 HIV-1 (mouse) and purified HIV-1 and HIV-2 antigens: 1 plate (96 tests)
   • **R2 Concentrated washing solution (20X)** Tris NaCl buffer pH 7.4 Preservative: ProClin™ 300 0.04%: 1 vial (70 ml)
   • **R3 Negative control** Heat inactivated human plasma negative for HBs antigen, HIV antigen, anti-HIV-1, anti-HIV-2 and anti-HCV antibodies Preservative: Sodium azide < 0.1%: 1 vial (2.5 ml)
   • **R4 HIV Ab positive control** Heat inactivated human plasma positive for anti-HIV antibodies, negative for HIV and HBs antigens and anti-HCV antibodies, in synthetic diluent Preservative: ProClin™ 300 < 0.1%: 1 vial (1 ml)
   • **R5 HIV Ag positive control** Purified HIV 1 antigen inactivated with a chaotropic agent, in synthetic diluent Preservative: ProClin™ 300 < 0.1%: 1 vial (1 ml)
   • **R6 Conjugate 1** biotinylated polyclonal antibodies to p24 HIV 1 (sheep) (2 x 10 ml) coloured yellow – green Preservative: ProClin™ 300 0.5%: 1 vial (10 ml)
   • **R7a Conjugate 2** Lyophilised peroxidase-labelled streptavidin and purified HIV 1 and HIV 2 antigens: 1 vial (12.5 ml)
   • **R7b Conjugate 2 Diluent** skimmed milk solution coloured red preservative: ProClin™ 300 0.5%: 1 vial (12.5 ml)
   • **R8 Peroxidase substrate buffer** Sodium citrate and sodium acetate solution pH 4.0 containing H₂O₂ (0.015%) and dimethyl sulfoxide DMSO (4%): 1 vial (60 ml)
   • **R9 Chromogen** solution containing tetramethyl benzidine (TMB): 1 vial (5 ml)
• **R10 Stopping solution** 1N sulphuric acid solution: 1 vial (28 ml)

2. **Genscreen™ ULTRA HIV Ag-Ab with product code 72388:**
   - **R1 Microplate** 12 strips of 8 wells coated with monoclonal antibodies to p24 HIV-1 (mouse) and purified HIV-1 and HIV-2 antigens: 5 plates (480 tests)
   - **R2 Concentrated washing solution (20X)** Tris NaCl buffer pH 7.4 Preservative: ProClin™ 300 0.04%; 1 vial (235 ml)
   - **R3 Negative control** Heat inactivated human plasma negative for HBs antigen, HIV antigen, anti-HIV-1, anti-HIV-2 and anti-HCV antibodies Preservative: Sodium azide < 0.1%; 1 vial (2.5 ml)
   - **R4 HIV Ab positive control** Heat inactivated human plasma positive for anti-HIV antibodies, negative for HIV and HBs antigens and anti-HCV antibodies, in synthetic diluent Preservative: ProClin™ 300 < 0.1%; 1 vial (1 ml)
   - **R5 HIV Ag positive control** Purified HIV 1 antigen inactivated with a chaotropic agent, in synthetic diluent Preservative: ProClin™ 300 < 0.1%; 1 vial (1 ml)
   - **R6 Conjugate 1** biotinylated polyclonal antibodies to p24 HIV 1 (sheep) (2 x 10 ml) coloured yellow – green Preservative: ProClin™ 0.5%: 2 vials (2x10 ml)
   - **R7a Conjugate 2** Lyophilised peroxidase-labelled streptavidin and purified HIV 1 and HIV 2 antigens: 2 vials (2x30 ml)
   - **R7b Conjugate 2 Diluent** skimmed milk solution coloured red preservative : ProClin™ 300 0.5%: 2 vials (2x30 ml)
   - **R8 Peroxidase substrate buffer** Sodium citrate and sodium acetate solution pH 4.0 containing H₂O₂ (0.015%) and dimethyl sulfoxide (4%): 2 vials (2x60 ml)
   - **R9 Chromogen** solution containing tetramethyl benzidine (TMB): 2 vials (2x5 ml)
   - **R10 Stopping solution** 1N sulphuric acid solution: 3 vials (3x28 ml)

Storage:
The test kit should be stored at 2 - 8°C.

Conservation:
**R1** In a reclosed bag, 4 weeks at +2-8°C
**R2** After dilution, 2 weeks at +2-8°C. Concentrated washing solution (R2) can be stored at +2-30°C.
**R7a + R7b** After the reconstitution, 1 month at +2-8°C. After the frozen reconstitution, until the expiry date of the kit, it can be frozen then unfrozen 11 times.
**R8 + R9** After the reconstitution, 6 hours at 18-30°C in the dark.

Shelf-life:
18 months.
Summary of prequalification status for Genscreen™ ULTRA HIV Ag-Ab

<table>
<thead>
<tr>
<th>Initial acceptance</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Status on PQ list</td>
<td>08 April 2013</td>
</tr>
<tr>
<td>Dossier assessment</td>
<td>28 March 2013</td>
</tr>
<tr>
<td>Inspection status</td>
<td>02 April 2013</td>
</tr>
<tr>
<td>Laboratory evaluation</td>
<td>21 December 2012</td>
</tr>
<tr>
<td>Date</td>
<td>Outcome</td>
</tr>
<tr>
<td>listed</td>
<td></td>
</tr>
<tr>
<td>MR</td>
<td></td>
</tr>
<tr>
<td>MR</td>
<td></td>
</tr>
<tr>
<td>MR</td>
<td></td>
</tr>
</tbody>
</table>

MR: Meets Requirements  
NA: Not Applicable

Genscreen™ ULTRA HIV Ag-Ab was accepted for the WHO list of prequalified diagnostics on the basis of data submitted and publicly available information.

Background information

Bio-Rad submitted an application for prequalification of Genscreen™ ULTRA HIV Ag-Ab. Based on the established prioritization criteria, Genscreen™ ULTRA HIV Ag-Ab was given priority for prequalification.

Product dossier assessment

Bio-Rad submitted a product dossier for Genscreen™ ULTRA HIV Ag-Ab as per the Instructions for compilation of a product dossier (PQDx_018 v1). The information submitted in the product dossier was reviewed by WHO staff and external experts (assessors) appointed by WHO in accordance with the internal report on the screening and assessment of a product dossier (PQDx_009 v2). Based on the product dossier screening and assessment findings, a recommendation was made to accept the product dossier for Genscreen™ ULTRA HIV Ag-Ab for prequalification.

Commitments for prequalification:
The manufacturer committed to amend and submit additional documentation on the following issues:
1. In-use stability studies
2. A new version of the instructions for use.

Manufacturing site inspection

A shortened inspection (29-31 May 2012) was performed at two of the sites of the legal manufacturer, Bio-Rad, located at Route de Cassel 59114 Steenvoorde (two days) and at 3, bd Raymond Poincare 92430 Marnes La Coquette (one day). The inspection for two
products, the Gensceen ULTRA HIV Ag-Ab test and the Monolisa HCV Ag-Ab ULTRA and was performed as per ‘Information for manufacturers on WHO prequalification inspection procedures for the sites of manufacture of diagnostics.’ (PQDx_014 v1).

The inspection was based on ‘ISO 13485:2003 Medical devices - Quality management systems - Requirements for regulatory purposes’ and other internationally recognized standards relevant to the manufacture of in vitro diagnostics. In addition, the claims made in the submitted product dossier were verified and the adequacy of mechanisms for lot release of the product to customers was audited. With consideration that the product should be suitable for use in resource limited settings, particular attention was paid to suitability of product labelling currently in use (including instructions for use and storage requirements), stability testing (in-use, transportation and storage stability), and effective mechanisms for customer training, service and feedback.

The inspection found that the legal manufacturer had an acceptable quality management system and good manufacturing practices that ensured the consistent manufacture of a product of good quality. The manufacturer’s final responses to the nonconformities found at the time of the inspection were accepted 02 April 2013.

Commitments for prequalification:

1. The manufacturer has committed to addressing nonconformities found at the WHO inspection, including updating real time stability studies.
2. The manufacturer has committed to an acceptable timeline for updating the risk analysis and risk management, and has announced the appointment of a Risk Analysis Specialist to the Bio-Rad team.
3. The manufacturer has committed to the revision of the Instructions for Use that will take into account the WHO remarks regarding suitability for end users in resource limited settings.

Laboratory evaluation

Genscreen™ ULTRA HIV Ag-Ab (Bio-Rad) is an enzyme immunoassay for the combined detection of HIV-1/2 antibodies and HIV-1 p24 antigen in human serum and plasma. A volume of 75 µl of specimen is needed to perform the assay. This type of assay requires laboratory equipment and cannot be performed in laboratories with limited facilities. Reading of the results must be performed with a spectrophotometer.

In this limited performance evaluation on a panel of 1120 specimens, we found an initial sensitivity (95% CI) of 100% (99.2% - 100%) and an initial specificity (95% CI) of 99.09% (98.0% - 99.7%) compared to the reference results. The final sensitivity (95% CI) was 100% (99.2% - 100%) and the final specificity (95% CI) was 99.24% (98.2% - 99.8%) compared to the reference results. Lot to lot variation observed was within the acceptance range.
For eight seroconversion panels, Genscreen™ ULTRA HIV Ag-Ab detected on average 1.375 specimens earlier than the benchmark assay (Enzygnost Anti-HIV 1/2 Plus [Siemens Healthcare Diagnostics] EIA) and on average 0.750 specimens earlier than Vironostika HIV Ag/Ab (bioMérieux) EIA.

For the mixed titer panel, Genscreen™ ULTRA HIV Ag-Ab classified one specimen as false positive, all other specimens were correctly identified. For the HIV-1 p24 antigen panel, Genscreen™ ULTRA HIV Ag-Ab correctly classified all specimens. For the HIV culture supernatant panel, Genscreen™ ULTRA HIV Ag-Ab detected all HIV-1 subtypes, the HIV-2 culture isolate was also detected.

For the 1st International Reference Panel for anti-HIV [NIBSC code 02/210], Genscreen™ ULTRA HIV Ag-Ab detected all subtypes tested (HIV-1 A, HIV-1 B, HIV-C, HIV-1 CRF01_AE, HIV-1 O and HIV-2). For the HIV-1 p24 antigen standard [NIBSC code 90/636], Genscreen™ ULTRA HIV Ag-Ab detected to 0.78 international units). In contrast, Vironostika HIV Ag/Ab (bioMérieux) detected to 12.5 international units.

In this study, 0.18% of the results were recorded as indeterminate. The invalid rate was 0%.
Labelling

1. Labels
2. Instructions for use
1. Labels

1.1. Product code 72386:

**Genscreen™ ULTRA HIV Ag-Ab**

72386

**SCREENING KIT FOR THE DETECTION OF HIV P24 ANTIGEN AND ANTIBODIES TO HIV-1 IN HUMAN SERUM/PLASMA BY ENZYME IMMUNOASSAY**

96 Tests

1- Text printed on the box

Bio-Rad

3, Boulevard Raymond Poincaré

92430 Marnes-la-Coquette France

Tel.: +33 (0) 1 47 95 60 00

Fax: +33 (0) 1 47 41 91 33

2- Box labels

**R1**

1 x 1 Microplate: 12 strips of 6 wells coated with monoclonal antibodies to p24 HIV-1 (mouse) and purified HIV-1 and HIV-2 antigens

**R2**

1 x 20 ml Concentrated washing solution (200)

**R3**

1 x 2.5 ml Negative control

**R4**

1 x 1 ml HIV p24 positive control

**R5**

1 x 1 ml HIV Ag positive control

**R6**

1 x 10 ml Conjugate 1: Enzyme-p24 HIV-1 Ab sheep

**R7a**

1 x 1.25 ml Substrate buffer

**R7b**

1 x 60 ml Peroxidase substrate buffer (0.015% H2O2, 4% DM50)

**R8**

1 x 5 ml Chronogen: TMB solution

**R9**

1 x 20 ml Stopping solution (4% H2SO4)

**R10**

1 x 300 ml ProCine™ 300 (6.5%)

**R11**

1 x 300 ml ProCine™ 300 (6.15%)

**R12**

1 x 300 ml ProCine™ 300 (0.4%)
II-REAGENT LABELS

CONCENTRATED WASHING SOLUTION R2
20X 70 ml (20x)
+2°C - 30°C 73605
Bio-Rad - F 92430-Marnes la Coquette

GENSCREEN ULTRA HIV Ag-Ab
Negative control 2.5 ml
Bio-Rad - F 92430-Marnes la Coquette

GENSCREEN ULTRA HIV Ag-Ab
HIV Ag positive control 1 ml
Bio-Rad - F 92430-Marnes la Coquette

GENSCREEN ULTRA HIV Ag-Ab
Conjugate 1 10 ml
Bio-Rad - F 92430-Marnes la Coquette

GENSCREEN ULTRA HIV Ag-Ab
Conjugate 2 12.5 ml
Bio-Rad - F 92430-Marnes la Coquette

SUBSTRATE BUFFER R8
TMB buf. 60 ml
(0.015 % H2O2, DMSO)
+2°C - 8°C
Bio-Rad - F 92430-Marnes la Coquette

CHROMOGEN : TMB SOLUTION R9
TMB 11X 5 ml
Bio-Rad - F 92430-Marnes la Coquette

STOPPING SOLUTION R10
1N (H2SO4 1N)
28 ml
Bio-Rad - F 92430-Marnes la Coquette
2.1. Product code 72388:

Bio-Rad
3, Boulevard Raymond Poincaré
92430 Atmess-la-Coquette France
Tel. : +33 (0) 1 47 96 60 00
Fax : +33 (0) 1 47 41 91 33
2. Instructions for use

**Genscreen™ ULTRA HIV Ag-Ab**

1 plate - 96 tests  72386
5 plates - 480 tests  72388

(GB) • Other requested languages can be obtained from your local Bio-Rad agent. Imperatively use the package insert version mentioned on the box (\\\\\\\[GB]\\\\\\\\). (FR) • Pour obtenir d’autres langues, contacter votre agent Bio-Rad. Utiliser obligatoirement la version de la notice mentionnée sur la boîte (\\\\\\\[FR]\\\\\\\\). (ES) • Puede solicitar otros idiomas a su agente local Bio-Rad. Utilice obligatoriamente la píldora adjunta, versión indicada en la caja (\\\\\\\[ES]\\\\\\\\). (T) • E possibile avere i Manuali di Istruzioni in altre lingue richiedendoli al collaboratore Bio-Rad di zona. Utilizzare tattativamente il manuale di istruzioni della versione citata sulla confezione (\\\\\\\[T]\\\\\\\\). (DE) • Andere Sprachen sind auf Anfrage von Ihrem Bio-Rad-Vertragshändler oder direkt bei der Schachtel genannte Version der Verpackungseinfügung zu verwenden (\\\\\\\[DE]\\\\\\\\). (PT) • É possível obter outros idiomas solicitados junto da sua agência Bio-Rad local. Consulte obrigatoriamente a versão do folheto informativo referida na embalagem (\\\\\\\[PT]\\\\\\\\). (SE) • Andra språk kan fås av din lokala Bio-Rad återförsäljare. Använd alltid den version av bipackadelen som anges på förpackningen (\\\\\\\[SE]\\\\\\\\). (DK) • Hvis der ønskes andre sprog, kan de fås hos den lokale Bio-Rad-representant. Indlægsdelen, som er angivet på kassen, skal altid anvendes (\\\\\\\[DK]\\\\\\\\). (GR) • Οι άλλες απαραίτητες γλώσσες μπορείτε να τις πάρετε από τον τοπικό προμηθευτή σας Bio-Rad. Χρησιμοποιήστε την παραλλαγή του ενδείξιμου συσκευασίας που αναγράφεται στο κουτί (\\\\\\\[GR]\\\\\\\\). (PL) • Informację w innych językach można otrzymać u miejscowego przedstawiciela firmy Bio-Rad. Należy bezwzględnie zaopatrzony w ulotkę do pakietu wskazaną na opakowaniu (\\\\\\\[PL]\\\\\\\\). (LT) • Informaciją girtąja kalba galima gauti iš vietinio „Bio-Rad” atstovo. Privaloma naudoti iština paketo versiją, nurodytą ant dešutės (\\\\\\\[LT]\\\\\\\\). (HU) • Egyéb nyelveken a helyi Bio-Rad képviselettől szerezhető be. A dobozon szereplő verzioszámú tájékoztatót kell kotelező érvényvel használni (\\\\\\\[HU]\\\\\\\\). (EE) • Teie domises juhendi saate soovi korral kaldakult Bio-Rad asindajat. Konustuslik on kasutada karbli mainitud pakendi infolehe versiooni (\\\\\\\[EE]\\\\\\\\). (SK) • Ďalšie jazyky si môžete vyžiadať u svojho miestneho zástupcu Bio-Rad. Bezpodmienené používanie verzií príbalového letáku uvedených na škatúri (\\\\\\\[SK]\\\\\\\\). (CZ) • Ostatní požadované jazyky jsou k dispozici u vašeho místního prodejce Bio-Rad. Použijte pouze verzi príbalového letáku uvedenou na obalu (\\\\\\\[CZ]\\\\\\\\). (RO) • A alta limba solicitate pot fi obtinută de la agentul dumneavoastră local Bio-Rad. Este imperativ să utilizați versiunea prospectului menționată pe cutie (\\\\\\\[RO]\\\\\\\\). (BG) • Други езици можете да получите от представителя на Bio-Rad. Задължително използвайте варианта на листовката, описан върху опаковката (\\\\\\\[BG]\\\\\\\\). (LY) • Citas pieprasitas valcas varat legut no Jusu všiekuj Bio-Rad přístroj. Notexiki izmantojiet pieprasātā lietošanas norādījumus, kas norādīts uz iepakojuma (\\\\\\\[LY]\\\\\\\\). (MT) • Lingwi oħrajn mittlibun jistgħu jinkjabs minħand l-agent ta’ Bio-Rad lokali tiegħek. Huwa misterri li tizu l-verżjoni tal-rujx tal-tagħmir maṣmanija tuq il-kaxx (\\\\\\\[MT]\\\\\\\\). (NL) • Andere gevraagde talen kunnen worden verkregen bij uw plaatselijke Bio-Rad agent. Gabruck uit te laten dat op de doos vermelde versie van de bijlagen (\\\\\\\[NL]\\\\\\\\). (SI) • Druga želena jezika lahko dobite pri krajevni n zastopniku Bio-Rad. Obvezno uporabite različico navodil za uporabo, navedeno na škatli (\\\\\\\[SI]\\\\\\\\). (FI) • Muita kielta on saatavilla omalta Bio-Rad -edustajain. Käyttäjäehottomasti laitakossa mainittua tuoteoseluversiota (\\\\\\\[FI]\\\\\\\\).
Genscreen™ ULTRA HIV Ag-Ab
1 plate - 96 tests  72386
5 plates - 480 tests  72388

SCREENING KIT FOR THE DETECTION OF HIV P24 ANTIGEN
AND ANTIBODIES TO HIV-1 AND HIV-2 IN HUMAN
SERUM/PLASMA BY ENZYME IMMUNOASSAY

[IVD] For In Vitro Diagnostic Use

Manufacturer Quality Control
All manufactured and commercialised reagents are under complete quality system starting
from reception of raw material to the final commercialisation of the product.
Each lot is submitted to a quality control and only is released on the market when
conforming to the acceptance criteria.
The records relating to production and control of each single lot are kept within our
company.
CONTENTS

1. INTENDED USE
2. CLINICAL VALUE
3. PRINCIPLE OF THE Genscreen™ ULTRA HIV Ag-Ab
4. CONTENTS OF THE Genscreen™ ULTRA HIV Ag-Ab
5. PRECAUTIONS
6. HEALTH AND SAFETY INSTRUCTION
7. MATERIAL REQUIRED BUT NOT PROVIDED
8. PREPARATION OF REAGENTS
9. STORAGE CONDITIONS - SHELF LIFE
10. COLLECTION AND HANDLING OF SPECIMENS
11. ASSAY PROCEDURE
12. SYSTEM ADAPTATIONS
13. CALCULATION AND INTERPRETATION OF THE RESULTS
14. SPECTROPHOTOMETRIC VERIFICATION OF SAMPLE AND CONJUGATE PIPETING
15. PERFORMANCES
16. LIMITS OF THE TEST
17. REFERENCES
1. INTENDED USE
The Genscreen™ ULTRA HIV Ag-Ab is a qualitative enzyme immunoassay kit for the detection of HIV p24 antigen and antibodies to HIV-1 (groups M and O) and HIV-2 in human serum or plasma. This kit can be used for both HIV Ag and HIV Ab screening.

2. CLINICAL VALUE
The acquired immunodeficiency syndrome (AIDS) is a virus inducing infectious disease characterised by strongly depressed immunity.

Two types of viruses related to the Lentivirus group have been isolated from lymphocytes of patients suffering from AIDS or its premones. The first one, named HIV-1, was isolated in France then in the United States. The second one, named HIV-2 was isolated from two patients living in Africa and has proved to be responsible for a new AIDS focus in West Africa.

Knowledge on genetic variability of the HIV virus strains was acquired by sequencing the GAG, POL, and ENV genes of the representative strains of each subtype. The HIV-1 viruses are divided into 2 groups: the M group, including 9 sub-types (A to I) and the O group. The HIV-2 virus includes 5 sub-types. The geographical distribution of the different sub-types is now quite well defined. Some HIV-1 variants have only 70% homology for the GAG and POL genes with the main isolates and only 50% for the ENV gene; these differences can explain the failure of the diagnosis of infection in some patients.

The various HIV-2 isolates share common antigens with the SIV simian virus in all proteins (envelope proteins and core proteins: heterology = 30%), but exhibit less than 40% homology with the HIV-1 envelope proteins.

HIV antigens and antibodies appear and are detectable at different stages of the seroconversion and of the infection. The Genscreen™ ULTRA HIV Ag-Ab allows the simultaneous detection of anti-HIV-1 (M and O groups) and anti-HIV-2 antibodies and antigens (see also limitation of the procedure).

3. PRINCIPLE OF THE TEST
The Genscreen™ ULTRA HIV Ag-Ab is an enzyme immunoassay based on the principle of the sandwich technique for the detection of HIV antigen and of the various antibodies associated with HIV-1 and/or HIV-2 virus in human serum or plasma.

The solid phase is coated with:
- monoclonal antibodies against p24 HIV-1 antigen
- purified antigens: gp160 recombinant protein, a synthetic peptide mimicking a totally artificial (i.e. encoded by no existing virus) HIV-1 group O-specific epitope and a peptide mimicking the immunodominant epitope of the HIV-2 envelope protein.

The conjugates are based upon the use of:
- biotinylated polyclonal antibodies to HIV Ag (conjugate 1)
- Streptavidin and HIV antigens - peroxidase conjugate (gp41 and gp36 peptides mimicking the immunodominant epitopes of the HIV-1 and HIV-2 envelope glycoproteins, and the same synthetic peptide mimicking a totally artificial HIV-1 group O-specific epitope used for the solid phase) (conjugate 2)

The assay procedure includes the following reaction steps:
1. Conjugate 1 (biotinylated polyclonal antibody to p24 HIV-1 Ag) is added into the microplate wells.
2. Serum samples to be assayed and controls are pipetted into the wells.
   - If present, HIV antigens bind with the monoclonal antibody bound to the solid phase and the conjugate 1
   - HIV-1 and/or HIV-2 antibodies, if any, bind to the antigens immobilised on the solid phase.
   - Deposition of conjugate 1 and sample is validated through a colour change, from yellow-green to blue.
3. After incubation at 37°C then washing, conjugate 2 is added:
   - Streptavidin react with biotinylated Ab-Ag-Ab complexes
   - Peroxidase labelled, purified HIV-1 and HIV-2 antigens bind in turn to the IgG, IgM or IgA antibodies captured on the solid phase.
4. After incubation at 18-30°C the unbound conjugate 2 fraction is removed by washing. After incubation in presence of the substrate at room temperature (18-30°C) the presence of the complexed conjugate is shown by a change of colour.

5. The reaction is stopped and absorbances are read using a spectrophotometer at 450/620-700 nm. The absorbance measured on a sample determines the presence or absence of HIV Ag or HIV-1 and/or HIV-2 antibodies.

4. CONTENTS OF THE KIT

All reagents are exclusively for *in vitro* diagnostic use.

<table>
<thead>
<tr>
<th>LABEL</th>
<th>NATURE OF THE REAGENTS</th>
<th>PRESENTATION</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>72386</td>
</tr>
<tr>
<td>R1</td>
<td>Microplate</td>
<td>1 plate</td>
</tr>
<tr>
<td></td>
<td>12 strips of 8 wells coated with monoclonal antibodies to p24 HIV-1 (mouse) and purified HIV-1 and HIV-2 antigens</td>
<td></td>
</tr>
<tr>
<td>R2</td>
<td>Concentrated washing solution (20X)</td>
<td>1 vial</td>
</tr>
<tr>
<td></td>
<td>Tris NaCl buffer pH 7.4</td>
<td>(70 ml)</td>
</tr>
<tr>
<td></td>
<td>Preservative : ProClin™ 300 0.04%</td>
<td></td>
</tr>
<tr>
<td>R3</td>
<td>Negative control</td>
<td>1 vial</td>
</tr>
<tr>
<td></td>
<td>Heat inactivated human plasma negative for HBs antigen, HIV antigen, anti-HIV-1, anti-HIV-2 and anti-HCV antibodies</td>
<td>(2.5 ml)</td>
</tr>
<tr>
<td></td>
<td>Preservative : Sodium azide &lt; 0.1%</td>
<td></td>
</tr>
<tr>
<td>R4</td>
<td>HIV Ab positive control</td>
<td>1 vial</td>
</tr>
<tr>
<td></td>
<td>Heat inactivated human plasma positive for anti-HIV antibodies, negative for HIV and HBs antigens and anti-HCV antibodies, in synthetic diluent</td>
<td>(1 ml)</td>
</tr>
<tr>
<td></td>
<td>Preservative : ProClin™ 300 &lt; 0.1%</td>
<td></td>
</tr>
<tr>
<td>R5</td>
<td>HIV Ag positive control</td>
<td>1 vial</td>
</tr>
<tr>
<td></td>
<td>Purified HIV 1 antigen inactivated with a chaotropie agent, in synthetic diluent</td>
<td>(1 ml)</td>
</tr>
<tr>
<td></td>
<td>Preservative : ProClin™ 300 &lt; 0.1%</td>
<td></td>
</tr>
<tr>
<td>R6</td>
<td>Conjugate 1</td>
<td>1 vial</td>
</tr>
<tr>
<td></td>
<td>biotinylated polyclonal antibodies to p24 HIV 1 (sheep) coloured yellow - green</td>
<td>(10 ml)</td>
</tr>
<tr>
<td></td>
<td>Preservative : ProClin™ 300 0.5%</td>
<td></td>
</tr>
<tr>
<td>R7a</td>
<td>Conjugate 2</td>
<td>1 vial</td>
</tr>
<tr>
<td></td>
<td>Lyophilised peroxidase labelled Streptavidin and purified HIV 1 and HIV 2 antigens</td>
<td>(suf 12.5 ml)</td>
</tr>
<tr>
<td>R7b</td>
<td>Conjugate 2 Diluent</td>
<td>1 vial</td>
</tr>
<tr>
<td></td>
<td>kimmied milk solution coloured red preservative : ProClin™ 300 0.5%</td>
<td>(12.5 ml)</td>
</tr>
<tr>
<td>R8</td>
<td>Peroxidase substrate buffer</td>
<td>1 vial</td>
</tr>
<tr>
<td></td>
<td>Sodium citrate and Sodium acetate solution pH 4.0 containing H2O2 (0.015%) and DMSO (4%)</td>
<td>(60 ml)</td>
</tr>
<tr>
<td>R9</td>
<td>Chromogen</td>
<td>1 vial</td>
</tr>
<tr>
<td></td>
<td>solution containing tetramethyl benzidine (TMB)</td>
<td>(5 ml)</td>
</tr>
<tr>
<td>R10</td>
<td>Stopping solution</td>
<td>1 vial</td>
</tr>
<tr>
<td></td>
<td>1N sulphuric acid solution</td>
<td>(28 ml)</td>
</tr>
</tbody>
</table>
5. PRECAUTIONS
The reliability of the results depends on correct implementation of the following Good Laboratory Practices:

- The name of the test, as well as a specific identification number for the test, are written on the frame of each microtiter plate. This specific identification number is stated on each strip too.

*Genscreen™ ULTRA HIV Ag-Ab: Specific ID number = 53*

Verify the specific identification number before use. If the identification number is missing, or different from the stated number above, the strip should not be used.

- Do not use expired reagents.
- Do not mix reagents from different lots within a given test run.

**REMARK:** For washing solution (R2, label identification: 20X coloured green), peroxidase substrate buffer (R8, label identification: TMB buf., coloured blue), chromogen (R9, label identification: TMB 11X coloured purple) and stopping solution (R10, label identification: 1N coloured red), it is possible to use other lots than those contained in the kit, provided the same lot is used within a given test run. These reagents can be used with some other Bio-Rad products. In addition, the wash solution (R2, label identification: 20X coloured green) can be mixed with the 2 other wash solutions included in various Bio-Rad Reagent kits (R2, label identifications: 10X coloured blue or 10X coloured orange) when properly reconstituted, provided only one mixture is used within a given test run. Contact our technical service for detailed information.

- Before use, it is necessary to wait 30 minutes for the reagents to stabilise to room temperature.
- Carefully reconstitute the reagents avoiding any contamination.
- Do not carry out the test in the presence of reactive vapours (acid, alkaline, aldehyde vapours) or dust that could alter the enzyme activity of the conjugates.
- Use glassware thoroughly washed and rinsed with deionized water or preferably, disposable material.
- Do not allow the microplate to dry between the end of the washing operation and the reagent distribution.
- Waiting time between the dispensing of the conjugate 1 and the samples doesn’t have to exceed 10 minutes.
- The enzyme reaction is very sensitive to metal ions. Consequently, do not allow any metal element to come into contact with the various conjugate or substrate solutions.
- The development solution (substrate buffer + chromogen) must be coloured pink. The modification of this pink colour within a few minutes of reconstitution indicates that the reagent cannot be used and must be replaced. Preparation of the development solution can be made in a clean disposable single use plastic tray or glass container that has first been pre-washed with 1N HCl and rinsed thoroughly with distilled water and dried. This reagent must be stored in the dark.

- Use a new distribution tip for each sample.
- Well washing is a critical step in this procedure: respect the recommended number of washing cycles and make sure that all wells are completely filled and then completely emptied. Incorrect washing may lead to inaccurate results.
- Never use the same container to distribute conjugate and development solution.
- Check the pipettes and other equipment for accuracy and correct operation.
- Do not change the assay procedure.

6. HEALTH AND SAFETY INSTRUCTIONS
- All the reagents included in the kit are intended for “in vitro diagnostic use” and for professional use.
- This test kit should be handled only by qualified personnel trained in laboratory procedures and familiar with their potential hazards. Wear appropriate protective clothing, including lab coat, eye/face protection and disposable gloves (synthetic, non-latex gloves are recommended) and handle reagents and patient samples with the requisite Good Laboratory Practices. Wash hands thoroughly after performing the test.

- Do not pipette by mouth.
- Human origin material used in the preparation of the negative control (R3) has been tested and found non reactive for hepatitis B surface antigen (HBs Ag), HIV antigen, antibodies to hepatitis C, and antibodies to human immunodeficiency virus (HIV-1 and HIV-2).
• Human origin material used in the preparation of HIV-1 antibodies positive control (R4) has been tested and found non reactive for hepatitis B surface antigen (HBs Ag) and antibodies to hepatitis C.
• HIV Ag positive control (R5) has been inactivated using a chaotropic agent.
• Because no known test method can offer complete assurance that infectious agents are absent, handle reagents and patient samples as if capable of transmitting infectious disease.
• Any equipment directly in contact with specimens and reagents as well as the washing solutions should be considered as contaminated products and treated as such.
• Avoid spilling samples or solutions containing samples.
• Spills must be rinsed with bleach diluted at 10%. If the contaminating fluid is an acid, spills must be initially neutralised with sodium bicarbonate and dried with absorbent paper. The material used for cleaning must be discarded in a contaminated residue container.
• Samples and reagent of human origin, as well as, contaminated material and products must be discarded after decontamination:
  - either by immersion in bleach at a final concentration of 5% of sodium hypochlorite (1 volume of bleach for 10 volumes of contaminated fluid or water) for 30 minutes
  - or by autoclaving at 121°C for 2 hours minimum. Autoclaving is the best method to inactivate the HIV and the HBV viruses.
  - DO NOT PLACE SOLUTIONS CONTAINING SODIUM HYPOCHLORITE IN THE AUTOCLAVE.
• Do not forget to neutralise and/or autoclave the solutions or washing wastes or any fluid containing biological samples before discarding them into the sink.
• Some reagents contain ProClin™ 300 (0.04%, 0.1% and/or 0.5%).

Xi : Irritant
R43 : May cause sensitisation by skin contact.
S28-37 : After contact with skin, wash immediately with plenty of soap and water. Wear suitable gloves.

• The Safety Data Sheet is available upon request.
• Chemicals should be handled and disposed of in accordance with Good Laboratory Practices.
• Avoid any contact of the substrate buffer, the chromogen and the stopping solution with the skin and mucosa (toxicity, irritation or burn hazard).
• Some reagents contain sodium azide as a preservative. Sodium azide may react with laboratory plumbing to form copper or lead azides. Such azides are explosive. To prevent azide build-up, flush the pipes with a large quantity of water if solutions containing azide are disposed of in the sink after inactivation.

7. MATERIAL REQUIRED BUT NOT PROVIDED
• Distilled water.
• Sodium hypochlorite (household bleach) and sodium bicarbonate.
• Automatic or semiautomatic, adjustable or preset pipettes or multipipettes to measure and disperse 25 μl, 75 μl, 80 μl and 100 μl.
• Graduated cylinders of 25 ml; 100 ml; 1 000 ml capacity.
• Container for biohazardous waste.
• Water-bath or equivalent microplate incubator, thermostatically set at 37°C ± 1°C (\(^\circ\)).
• Manual, semiautomatic or automatic microplate washer (\(^\star\)).
• Microplate reader equipped with 450 nm, 490 nm and 620-700 nm filters (\(^\star\)).
• Absorbent paper.

\(^\star\) Consult us for detailed information about the equipment recommended by our technical department.

8. PREPARATION OF THE REAGENTS

NOTE: Before use, allow reagents to reach room temperature (19-30°C).

1) Ready for use reagents
Reagent 1 (R1) : Microplate
Each frame support containing 12 strips is wrapped in a sealed foil bag. Cut the bag using scissors or a scalpel 0.5 to 1 cm above the sealing. Open the bag and take out the frame. Put the unused strips back into the bag. Close the bag carefully and put it back into storage at +2-8°C.
Reagent 3 (R3) : Negative control
Reagent 4 (R4) : HIV Ab positive control
Reagent 5 (R5) : HIV Ag positive control
Reagent 6 (R6) : Conjugate 1
Reagent 10 (R10) : Stopping solution

2) Reagents to reconstitute
Washing solution (20X concentrate) : Reagent 2 (R2)
Dilute 1:20 in distilled water to obtain the ready-for-use washing solution. Prepare 800 ml for one plate of 12 strips.

Conjugate 2 working solution : Reagent 7a (R7a) + Reagent 7b (R7b)
Gently tap the vial of the lyophilised conjugate 2 (R7a) on the workbench to remove any substance from the rubber cap. Carefully remove the cap and pour the contents of Conjugate Diluent vial (R7b) into the Lyophilised Conjugate vial (R7a). Replace the cap and let stand for 10 minutes, whilst gently shaking and inverting from time to time to ease dissolution.

Enzyme development solution : Reagent 8 (R8) + Reagent 9 (R9)
Dilute 1:11 the chromogen (R9) in the Substrate Buffer (R8) (ex : 1 ml reagent R9+10 ml reagent R8). Stability is for 6 hours in the dark once prepared.

9. STORAGE CONDITIONS - SHELF LIFE
The kit should be stored at +2-8°C. When stored at this temperature, each reagent contained in the Genscreen™ ULTRA HIV Ag-Ab can be used until the expiry date mentioned on the package (except for specific instructions).

R1 : After the vacuum-sealed bag has been opened, the microwell strips stored at +2-8°C in the carefully resealed bag can be used for 1 month.
R2 : The diluted washing solution can be stored at +2-30°C during 2 weeks. The concentrated washing solution (R2) can be stored at +2-30°C.
R7a + b : The reagents stored at +2-8°C can be used for 4 weeks after the vials have been reconstituted. The frozen reconstituted conjugate (R7 a+b) can be used until the expiry date of the kit, it can be frozen then defrozen 11 times.
R8 + R9 : After the reconstitution, the reagent stored in the dark can be used for 6 hours at room temperature (18-30°C)

10. COLLECTION AND HANDLING OF SPECIMENS
Collect a blood sample according to the current practices. The test should be performed on undiluted serum or plasma (collected with EDTA, heparin, citrate, ACD-based anticoagulants). Separate the serum or plasma from the clot or red cells as soon as possible to avoid any haemolysis. Extensive haemolysis may affect test performance. Specimens with observable particulate matter should be clarified by centrifugation prior testing. Suspended fibrin particles or aggregates may yield falsely positive results.
Do not heat the samples.
The specimens can be stored at +2-8°C if screening is performed within 7 days or they may be deep-frozen at -20°C for several months. The plasma must be quickly thawed by warming for a few minutes in a water bath at 40°C (To avoid fibrin precipitation). Do not repeat more than 3 freeze/thaw cycles.
If the specimens are to be shipped, they must be packaged in accordance with the regulations in force regarding the transport of etiological agents.
DO NOT USE CONTAMINATED, HYPERLIAPAEMIC OR HYPERHEMOLYSED SERA OR PLASMA.
REMARK : Samples containing up to 90 g/l albumin, 200 mg/l bilirubin, 50 µg/l bilirubin, lipemic samples containing up to the equivalent of 36 g/l triglyceride, and hemolyzed samples containing up to 10 g/l haemoglobin do not affect the results.

11. ASSAY PROCEDURE
Strictly follow the proposed procedure.
Use the negative (R3), HIV-1 Ab positive (R4) and HIV Ag positive (R5) controls for each series of determinations to validate the test results.
Follow the following Good Laboratory Practice :
1. Carefully establish the sample distribution and identification plan.
2. Prepare the diluted washing solution (refer to chapter 8).
3. Prepare the conjugate 2 working solution (refer to chapter 8).
4. Take the carrier tray and the strips (R1) out of the protective pouch,
5. Apply directly, without prior washing of the plate and in succession (suggested plate distribution):
   5.1 25 µl of conjugate 1 (R6) in each well
   5.2 75 µl of HIV Ag positive control (R5) in well A1
        75 µl of HIV Ab positive control (R4) in well B1,
        75 µl of negative control (R3) in well C1, D1 and E1
        75 µl of specimen 1 in well F1
        75 µl of specimen 2 in well G1, etc. . . .
Homogenise the mixture by a minimum of 3 aspirations with 75 µl pipette or by shaking the microplate after the pipetting step.
Depending on the used system, it is possible to modify the position of controls or the order of distribution.
   N.B.: The sample and conjugate 1 distribution can be visually controlled at this step of the manipulation: after adding the sample, the conjugate 1 turns from yellow - green to blue (refer to section 14 for automatic verification: SPECTROPHOTOMETRIC VERIFICATION OF SAMPLE AND REAGENTS PIPETING).
6. When possible, cover the microplate with adhesive film. Press firmly all over the plate to ensure a tight seal.
7. Incubate the microplate in a thermostat-controlled water-bath or microplate incubator at 37°C ± 1°C for 1 hour ± 4 minutes.
8. Remove the adhesive film. Aspirate the contents of all wells into a container for biohazardous waste (containing sodium hypochlorite). Add into each well a minimum of 0.370 ml of washing solution. Allow a soak time of at least 30 seconds. Aspirate again. Repeat this procedure a minimum of two times (i.e. in total of a minimum of three washes). The residual volume must be lower than 10µl (if necessary dry the plate by turning it upside down on absorbent paper). If an automatic washer is used, follow the same procedure (refer to section 12: SYSTEM ADAPTATION)
9. Quickly dispense 100 µl of conjugate 2 solution (R7a + R7b) into all wells, the conjugate must be shaken before use.
   N.B.: The distribution of the conjugate 2, which is coloured red, can be visually controlled at this step of the manipulation. (refer to section 14 for automatic verification: SPECTROPHOTOMETRIC VERIFICATION OF SAMPLE AND REAGENTS PIPETING)
10. When possible, cover the plate with new adhesive film and incubate for 30 minutes ± 4 minutes at Room temperature (18 - 30°C).
11. Remove the adhesive film, empty all wells by aspiration and wash a minimum of 5 times as described above. The residual volume must be lower than 10 µl (if necessary, dry the strips by turning them upside down on absorbent paper.)
12. Quickly dispense into each well 80µl of prepared substrate solution (R8+R9), freshly prepared before use. Allow the reaction to develop in the dark for 30 ± 4 minutes at room temperature (18 - 30°C). Do not use adhesive film during this incubation.
   N.B.: The distribution of the development solution, which is coloured pink, can be visually controlled at this step of the manipulation: There is a clear difference of colouration between empty well and well containing the pink substrate solution. (refer to section 14 for automatic verification: SPECTROPHOTOMETRIC VERIFICATION OF SAMPLE AND REAGENTS PIPETING)
13. Add 100 µl stopping solution (R10) by using the same sequence and rate of distribution as for the substrate solution.
   N.B.: The distribution of the stopping solution, which is not coloured, can be visually controlled at this step of the manipulation. After the addition of the stopping solution the pink colouration of the substrate disappears (for the negative samples) or turns from blue to yellow (for the positive samples)
14. Carefully wipe the plate bottom. At least 2 minutes after stopping solution addition and within 30 minutes of stopping the reaction, read the optical density at 450/620-700 nm using a plate reader within 30 minutes of stopping the reaction (the strips must always be kept away from light before reading).

15. Check for agreement between the spectrophotometric and visual readings and against the plate and sample distribution and identification plans.

12. SYSTEM ADAPTATION
   WASHING: Carefully follow the washing procedures described to obtain maximum test performance.

13. CALCULATION AND INTERPRETATION OF THE RESULTS
    The presence or absence of detectable HIV Antigen or antibodies to HIV-1 and/or HIV-2 is determined by comparing the absorbance measured for each sample to the calculated cut-off value.

1) Calculate the mean absorbance of the negative control (OD R3)
   \[ \text{OD R3} = \frac{\text{OD (C1)} + \text{OD (D1)} + \text{OD (E1)}}{3} \]

2) Calculate the cut-off value
   The cut-off value is given by the formula:
   \[ \text{CO} = \text{OD R3} + 0.200 \]

3) Assay validation
   The absorbance of each negative control (R3) should be less than 0.170: OD R3 < 0.170
   If one negative control does not respect this norm, disregard and recalculate the mean using the two remaining values. Only one value may be eliminated by this way.
   The mean of the absorbance of the negative controls (R3) should be less than 0.150: \[ \text{OD R3} < 0.150 \]
   The absorbance of HIV Ab positive control (R4) should be greater than 0.9: OD R4 > 0.9
   The absorbance of HIV Ag positive control (R5) should be greater than 0.9: OD R5 > 0.9

4) Interpretation of the results
   Samples with absorbance values less than the cut-off value are considered to be negative by the Genscreen™ ULTRA HIV Ag-Ab test.
   Results just below the cut-off value (C.O -10% < OD < C.O) should however, be interpreted with caution (it is advisable to retest in duplicate the corresponding samples when the systems and laboratory procedures permit).
   Samples with absorbance values equal to or greater than the cut-off value are initially considered to be positive by the Genscreen™ ULTRA HIV Ag-Ab test. They should be retested in duplicate before final interpretation.
   If after retesting of a sample, the absorbance values of the 2 duplicates are less than the cut-off value, the initial result is non-repeatable and the sample is declared to be negative with the Genscreen™ ULTRA HIV Ag-Ab test.
   Non repeatable reactions are often caused by:
   - inadequate microplate washing,
   - contamination of negative samples by serum or plasma with a high antibody titre,
   - contamination of the substrate solution by oxidising agents (bleach, metal ions, etc...),
   - contamination of the stopping solution.
   If after retesting the absorbance of one of the duplicates is equal to or greater than the cut-off value, the initial result is repeatable and the sample is declared to be positive with the Genscreen™ ULTRA HIV Ag-Ab test, subject to the limitations of the procedure, described below.

14. SPECTROPHOTOMETRIC VERIFICATION OF SAMPLE AND REAGENTS
   PIPETTING
   Sample and Conjugate 1 pipetting verification
   After the dispensing of the conjugate 1 (R6) and of the samples, it is possible to verify the simultaneous presence of the conjugate 1 and the samples to be tested into wells by a spectrophotometric reading at 620 nm: the optical density of a well containing conjugate 1 and sample is greater than 0.600 (a lower OD indicates poor dispensing of the conjugate 1 or of the sample).
Conjugate 2 working solution pipetting verification
After the dispensing of the conjugate (R7a + R7b) it is possible to verify its presence by a
spectrophotometric reading at 450 / 620 nm : the optical density of a well containing conjugate 2 is
greater than 0.100 (a lower OD indicates a poor dispensing of the conjugate 2)

Development solution pipetting verification
It is possible to verify the presence of pink development solution into the well by automatic reading
at 490 nm : a well with development solution must have an optical density greater than 0.100 (a lower
OD indicates a poor dispensing of the development solution)

15. PERFORMANCES
The performances of Genscreen™ ULTRA HIV Ag-Ab have been determined by testing samples from
random blood donors, from patients with HIV infection and commercial seroconversion panels.
Moreover the HIV Ag sensitivity limit has been tested using French AFSSAPS Standard.
Patients with diseases unrelated to HIV infection have been tested too.

Specificity
Specificity has been evaluated by testing :
1. 6038 random blood donors from 3 different sites. Specificity on random blood donors was 99.95%
(6035 negative samples / 6038 tested samples) with 3 repeated reactive samples which were
confirmed negative for HIV by Western Blot and HIV p24 Ag testing.
2. 409 clinical samples in 2 hospital clinical laboratories, 14 samples were found initial reactive
and 12 of them were repeatedly reactive (positive in a second testing) : 11 were confirmed by
HIV Western-Blot, 1 was not confirmed and considered as false positive. Specificity on this
population is (397/398) 99.75%.
3. 313 patients showing different pathologies or status not linked to the HIV (pregnant women,
rheumatoid factor, autoimmune (SLE), cirrhotic, chronic renal failure, dialysis, anti-mouse Ig or
other viral or bacterial infections (Hepatitis A, B, C, rubella, Toxoplasmosis, Mumps, Measles, CMV,
HSV, EBV, VZV, HTLVI, Malarial, Flu vaccinated patients). Specificity was 98.72% (309/313) with 4
non specific and non significant reactions.

Sensitivity
Sensitivity has been evaluated by testing confirmed HIV Ab positive samples, specimens from acute
infected patients and from commercial seroconversion panels and HIV Ag samples (neat or diluted)
1) Confirmed HIV Ab positive samples
744 positive samples from follow-up of HIV-1 and HIV 2 infected patient have been tested. This study
was showing a sensitivity of 100%.

<table>
<thead>
<tr>
<th>Types</th>
<th>Number of samples</th>
<th>Number of reactive samples</th>
<th>Sensitivity</th>
</tr>
</thead>
<tbody>
<tr>
<td>HIV 1</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>A, B, C (CDC classification)</td>
<td>200</td>
<td>200</td>
<td>100%</td>
</tr>
<tr>
<td>HIV-1 WB with complete profiles or with light anti-gag Ab bands</td>
<td>200</td>
<td>200</td>
<td>100%</td>
</tr>
<tr>
<td>VIH 1 group M (18A, 71B, 23C, 9D, 12 E, 4 F)</td>
<td>118</td>
<td>118</td>
<td>100%</td>
</tr>
<tr>
<td>Group O</td>
<td>22</td>
<td>22</td>
<td>100%</td>
</tr>
<tr>
<td>Group N</td>
<td>1</td>
<td>1</td>
<td>100%</td>
</tr>
<tr>
<td>BB1 PRZ 204 panel</td>
<td>7</td>
<td>7</td>
<td>100%</td>
</tr>
<tr>
<td>HIV 2</td>
<td>196</td>
<td>196</td>
<td>100%</td>
</tr>
</tbody>
</table>

25 additional fresh positive samples (within 1 day after blood collection) were tested and all were found positive.
2) Specimens from acute infected patients and from commercial seroconversion panels
- 81 specimens sourced from acute or recently HIV-1 infected patients (35 samples from 28 patients with a Western-Blot seroconversion profile and 46 samples from recent seroconversion) were found positive with Genscreen™ ULTRA HIV Ag-Ab.
- 20 per-seroconversion samples (very early seroconversion samples with negative Western-Blot profile or with very light band for p24 and/or gp160 on HIV Western-blot) : 19 of them were found positive.
- A total of 90 well documented commercial HIV seroconversion panels were also studied and compared to commercially available EIA assays. From which results were compared on 85 panels to a CE marked Ag-Ab test : Genscreen™ PLUS HIV Ag-Ab.

<table>
<thead>
<tr>
<th>Genscreen™ ULTRA HIV Ag-Ab Results compared to Genscreen™ PLUS HIV Ag-Ab</th>
<th>Earlier detection (at least one bleed)</th>
<th>Equivalent detection (Same sample recognized as positive)</th>
<th>Later detection</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of seroconversions</td>
<td>44</td>
<td>41</td>
<td>0</td>
</tr>
</tbody>
</table>

At least 170 early seroconversion samples were tested with Genscreen™ ULTRA HIV Ag-Ab.

3) HIV Ag samples

**Analytical sensitivity**: sensitivity limit of the test calculated by interpolation of the curve obtained by testing of dilutions of the AFSSAPS standard (initial concentration 100 pg/ml) was found to be < 25 pg/ml.

During the external evaluations, the limit of detection was established at 13.6 pg/ml by regression of the standard range of the “Ag HIV SFTS 1998” panel (HIV Ag panel from the French Society of Blood Transfusion).

The limit of detection has been estimated inferior to 2 IU/ml by testing the WHO HIV P24 Antigen 1st International Reference NIBSC code 90/636 and found at 0.85 IU/ml CI 95% [0.73 - 1.01 IU/ml] with 4 different batches during internal evaluation.

**Sensitivity on HIV Ag positive samples**: 56 samples were tested : 53 samples containing at least 25 pg/ml of HIV Ag were positive and 3 samples with respectively 13, 16 and 19 pg/ml of HIV Ag had ratios (Optical Density / Cut-off) between 0.9 and 1.00

**Sensitivity on culture cells supernatants**: 83 supernatants from the following genotypes were tested : 76 HIV-1 group M samples (16 A, 16 B, 11 C, 7D, 13 E, 4 F, 4 G, 3 H, 2 J), 4 HIV-1 group O, 1 HIV-1 group N and 2 HIV 2 samples. All of the HIV-1 samples were reactive except one group O sample with a concentration of 29 pg/ml of HIV Ag which was found with a ratio (Optical density / Cut off) of 0.60.

**Assay Reproducibility**

The reproducibility of Genscreen™ ULTRA HIV Ag-Ab test has been determined, by the analysis of 10 samples : 1 negative sample, 3 HIV 1 positive samples, 3 HIV 2 positive samples and 3 Antigen positive. The intra assay reproducibility has been evaluated by testing these 10 samples 30 times in the same run. The inter assay reproducibility has been evaluated by testing these 10 samples in duplicate during 20 days on 2 independent runs each days. Results are shown in the following tables:

**Table 1: Intra assay reproducibility**

<table>
<thead>
<tr>
<th>Samples</th>
<th>Mean Ratio</th>
<th>SD</th>
<th>CV%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Negative</td>
<td>0.28</td>
<td>0.02</td>
<td>5.37</td>
</tr>
<tr>
<td>HIV-1</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Low positive</td>
<td>1.62</td>
<td>0.07</td>
<td>4.32</td>
</tr>
<tr>
<td>Medium positive</td>
<td>2.98</td>
<td>0.13</td>
<td>4.33</td>
</tr>
<tr>
<td>High positive</td>
<td>5.37</td>
<td>0.18</td>
<td>3.32</td>
</tr>
<tr>
<td>HIV-2</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Low positive</td>
<td>2.5</td>
<td>0.18</td>
<td>7.20</td>
</tr>
<tr>
<td>Medium positive</td>
<td>5.35</td>
<td>0.45</td>
<td>8.48</td>
</tr>
<tr>
<td>High positive</td>
<td>11.19</td>
<td>0.58</td>
<td>5.21</td>
</tr>
<tr>
<td>HIV Ag</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Low positive</td>
<td>1.58</td>
<td>0.06</td>
<td>3.64</td>
</tr>
<tr>
<td>Medium positive</td>
<td>4.19</td>
<td>0.17</td>
<td>4.13</td>
</tr>
<tr>
<td>High positive</td>
<td>9.21</td>
<td>0.34</td>
<td>3.65</td>
</tr>
</tbody>
</table>
Table 2: Inter assay reproducibility

<table>
<thead>
<tr>
<th>Samples</th>
<th>Mean Ratio</th>
<th>SD</th>
<th>CV%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Negative</td>
<td>0.28</td>
<td>0.04</td>
<td>15.84</td>
</tr>
<tr>
<td>HIV-1</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Low positive</td>
<td>1.05</td>
<td>0.10</td>
<td>9.44</td>
</tr>
<tr>
<td>Medium positive</td>
<td>2.7</td>
<td>0.22</td>
<td>8.10</td>
</tr>
<tr>
<td>High positive</td>
<td>4.96</td>
<td>0.41</td>
<td>8.37</td>
</tr>
<tr>
<td>HIV-2</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Low positive</td>
<td>1.91</td>
<td>0.41</td>
<td>21.15</td>
</tr>
<tr>
<td>Medium positive</td>
<td>4.45</td>
<td>0.64</td>
<td>14.29</td>
</tr>
<tr>
<td>High positive</td>
<td>10.93</td>
<td>0.62</td>
<td>5.81</td>
</tr>
<tr>
<td>HIV Ag</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Low positive</td>
<td>1.29</td>
<td>0.08</td>
<td>6.48</td>
</tr>
<tr>
<td>Medium positive</td>
<td>3.48</td>
<td>0.17</td>
<td>4.99</td>
</tr>
<tr>
<td>High positive</td>
<td>8.91</td>
<td>1.11</td>
<td>12.48</td>
</tr>
</tbody>
</table>

16. LIMITS OF THE TEST

Very low titre of HIV antigen or antibodies may not be detected during the first stage of the infection, consequently a negative result indicates that the tested sample does not contain detectable HIV antigen or anti-HIV antibodies with Genscreen™ ULTRA HIV Ag-Ab. However, such a result does not preclude the possibility of exposure to an HIV 1 / HIV 2 infection. The variability of HIV-1 (group M and group O) and HIV 2 allows the possibility of false negative reactions. No known test method can offer complete assurance that the HIV virus is absent. Highly sensitive ELISA techniques may produce false positive results.

To verify the specificity of the reaction, every positive result (in accordance with the interpretation criteria of Genscreen™ ULTRA HIV Ag-Ab test) should be confirmed with an appropriate method (with a specific HIV Ag test such as the Genetic System HIV Ag EIA, then neutralisation to prove the presence of HIV Ag - or Western-Blot to prove the presence of anti-HIV antibodies).

Heating of samples may affect the quality of the results. The spectrophotometric method for verifying the sample, conjugate development solution deposition does allow to verify the accuracy of the dispensed volume of samples and conjugate. This method shows only the presence of sample and conjugate. The error rate with this method is closely linked to the accuracy of the utilised system (a cumulated coefficient of variation of over 10% for dispensing and reading will significantly decrease the quality of this step).

Some icteric hyperlipemic or hyperhemolysed samples may affect the spectrophotometric method for verifying the conjugate 1 deposition. Only the presence of sample can be verified in this case.

In case of very poor washing efficiency after the conjugate incubation, the automatic verification of the development solution pipetting (by reading OD of wells at 490 nm) may provide wrong results with OD above 0.100 in the absence of development solution. However this phenomena has not been observed during evaluation on 999 tested samples.

17. REFERENCES

1. BARRE-SINOUISS F., CHERMANN J.C., REY F. et al.  
2. BRUN-VEZINET F., ROUZIOUX C., BARRE-SINOUISS F. et al.  
   Detection of IgG antibodies to lymphadenopathy-associated in patients with Aids or lymphadenopathy syndrome. Lancet 1984, june, 1253-1256
3. CLAVER F., GUYADER M., GUETARD D. et al.  
4. NORRBY E., BIBERFELD G., JOHNSON PR. et al.  
   The chemistry of site-directed serology for HIV infections. AIDS Res Human Retroviruses 1989, 5, 487-493
5. MATHIESEN T., CHIODI F., BROLIDEN PA., et al.  
   Analysis of a subclass restricted HIV-1 gp 41 epitope by omission peptides. Immunology 1989, 67,1-7
   Immunogenicity and epitope mapping of a recombinant soluble gp 160 of the human
   immunodeficiency virus type 1 envelope glycoprotein AIDS Res. Human Retroviruses 1990, 6,
   1107-1113.
8. COURouce AM. and the other members of the retrovirus study group of the french society of
   blood transfusion. Effectiveness of assays for antibodies to HIV and p24 antigen to detect very
   recent HIV infections in blood donors. AIDS 1992, 6, 1548-1550
   Antigenic variation of the dominant gp 41 epitope in Africa. AIDS 1993, 7, 461-466.
10. CONSTANTINE N.T.
    Genomic cloning and complete sequence analysis of a highly divergent african human
    immunodeficiency virus isolate. J. Virology 1994, 68, 1586-1596.
12. GURTTLER L.G., HAUSER P.H., EBERLE J. et al.
    A new subtype of human immunodeficiency virus type 1 (MVP-5180) from Cameroon.
    J. Virology 1994, 1581-1585
13. NAIR B.C., FORD G., KALYANARAMAN V.S. et al.
    Enzyme immunoassay using native envelope glycoprotein (gp 160) for detection of human
    Genetic diversity of human immunodeficiency virus type 2 : evidence for distinct sequence
15. BUSCH M.P., SATTEN G.A.
    Time course of viremia and antibody seroconversion following human immunodeficiency virus
16. AUBUCHON J.P., BIRKMeyer J.D., BUSCH M.P.
    Cost-effectiveness of expanded human immunodeficiency virus-testing protocols for donated
    blood. Transfusion 1997, 37, 45-51.
17. WEBER B. et al.
    Reduction of diagnostic window by new fourth-generation human immunodeficiency virus
    Reduction of the diagnostic window with a new combined p24 antigen and human
19. SIMON F., MAUCLERE P., ROQUES P. et al.
    Identification of a new human immunodeficiency virus type 1 distinct from group M and group O.
20. COURouce AM. et le groupe de travail Rétrovirus de la Société Française de Transfusion
    18, 38-44.